Transcode therapeutics stock.

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Transcode Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data Transcode Therapeutics's RNAZ shares and potentially its market environment have been in bearish cycle last 12 months (if exists).

Transcode therapeutics stock. Things To Know About Transcode therapeutics stock.

Price Target. Only one analyst offered a short-term price target of $3.00 for TransCode Therapeutics Inc. This represents an increase of 1% from the last closing price of $0.24.TransCode Therapeutics press release (NASDAQ:RNAZ): Q3 Research and development expense was approximately $3.3 million Cash was approximately $7.5 million at September 30, 2023 Operating loss for ...TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...Further Supports TTX-MC138 Application in Brain Cancer. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX …

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously …BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...First Quarter 2022 Financial Highlights. Cash and cash equivalents were $16.9 million at March 31, 2022, compared to $20.8 million at December 31, 2021. Research and development expense was $1.9 ...

Find the latest TransCode Therapeutics Inc (RNAZ) discussion and analysis from iHub's community of investors.

The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeutic and appreciative.Among that is what’s happening with shares of PTC Therapeutics (NASDAQ:PTCT) stock, TransCode Therapeutics (NASDAQ:RNAZ) stock and Apollomics (NASDAQ:APLM) stock today. All of that info is ...BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 2,846,300 shares of common stock ...TransCode Therapeutics, Inc. Common Stock (RNAZ) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Transcode Therapeutics Inc stock performance at a glance. Check Transcode Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

BOSTON, Dec. 04, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its...

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its underwritten public offering of an aggregate of 15,700,000 shares of its common stock (or pre-funded ...

TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...In connection with the reverse stock split, the Company's CUSIP number will change to 89357L 204 as of 4:05 pm on Monday, May 22, 2023. About TransCode TherapeuticsUnderstanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ...The Trade: TransCode Therapeutics, Inc. RNAZ CEO Michael Robert Dudley acquired a total 18,607 shares an average price of $2.62. To acquire these shares, it cost around $48.66 thousand.

BOSTON, Dec. 04, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its...Get the latest Transcode Therapeutics Inc (RNAZ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Complete TransCode Therapeutics Inc. stock information by Barron's. View real-time RNAZ stock price and news, along with industry-best analysis.AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ...TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ...Get the latest Galera Therapeutics Inc (GRTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.1 brokerages have issued 12 month price objectives for TransCode Therapeutics' stock. Their RNAZ share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 4,976.1% from the stock's current price.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips. TransCode Therapeutics (NASDAQ:RNAZ) stock is taking a beating on Friday after the oncology company announced plans for a public ...TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same. However, despite significant efforts made in the past several ...

26 thg 11, 2023 ... TransCode Therapeutics, Inc. | 1341 followers on LinkedIn. Delivering a cancer-free future. | TransCode's lofty goal is delivering a ...Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively ...BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief …Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...Traders immediately bid up the RNAZ stock price this morning. It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ) stock. That’s because the company just disclosed the ...

May 22, 2023 · The 1-for-20 reverse stock split will automatically convert 20 current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in connection ...

Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per ...

On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 ...Dec 4, 2023 · TransCode Therapeutics hasn’t yet revealed details of the proposed public stock offering. RNAZ Trading at -49.61% from the 50-Day Moving Average After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.06% of loss for the given period. TransCode Therapeutics Inc RNAZ shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 clinical trial.The price trend for TransCode Therapeutics Inc. (RNAZ) has been bearish lately and the stock has lost 11.3% over the past two weeks. However, the formation of a hammer chart pattern in its last ...BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...

According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ...Among that is what’s happening with shares of PTC Therapeutics (NASDAQ:PTCT) stock, TransCode Therapeutics (NASDAQ:RNAZ) stock and Apollomics (NASDAQ:APLM) stock today. All of that info is ...TSLA Tesla, Inc. Common Stock $230.05 +0.01 BETR Better Home & Finance Holding Company Class A Common Stock $1.56 +0.41 +35.65% Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the... Thanksgiving is a time of gratitude, family, and gathering around a bountiful meal. While it’s often seen as a holiday for children, adults can also find joy and relaxation during this festive season. One activity that has gained popularity...Instagram:https://instagram. best pet insurance indianawine etfbest stocks for fully paid lendingfarm reits View the latest TransCode Therapeutics Inc. (RNAZ) stock price, news, historical charts, analyst ratings and financial information from WSJ. amprius technology stockdog elon mars TransCode Therapeutics Announces Public Offering of Common Stock. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology ... one up trader 14.50% of TransCode Therapeutics stock is owned by insiders. Learn more on RNAZ's insider holdings. Which TransCode Therapeutics insiders have been buying company stock? The following insiders have purchased RNAZ shares in the last 24 months: Robert Michael Dudley ($142,267.85), and Thomas A Fitzgerald ($25,168.50). ...Jul-08-21 06:34PM. TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering. (Business Wire) TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in ...